PIK3CA and extramammary Paget disease: A recently sequenced clinical cohort of vulvar EMPD identified targetable alterations in PIK3CA or ERBB2 in > 25% of patients, raising the possibility of novel therapeutic approaches, though whether these alterations occur in oral EMPD remains to be validated [21].